AMGEN INC 4
4 · AMGEN INC · Filed May 3, 2017
Insider Transaction Report
Form 4
AMGEN INCAMGN
Harper Sean E
EVP, Research & Development
Transactions
- Award
Common Stock
2017-05-01+4,551→ 60,496 total - Award
Nqso (Right to Buy)
2017-05-01+40,305→ 40,305 totalExercise: $162.60From: 2019-05-01Exp: 2027-05-01→ Common Stock (40,305 underlying)
Footnotes (4)
- [F1]The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively.
- [F2]These shares include the following RSUs granted under the Company's equity plans: 1,715 RSUs which vest on 1/31/2018; 2,640 RSUs which vest in two installments of 1,300 and 1,340 on 1/30/2018 and 1/30/2019, respectively; 4,477 RSUs which vest in two equal installments of 1,477 on 5/3/2018 and 5/3/2019 and one installment of 1,523 on 5/3/2020; and 4,551 RSUs which vest in installments of 1,501 on 5/1/2019, 1,502 on 5/1/2029 and 1,548 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- [F3]These shares include 386 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- [F4]These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively.